Published in BMC Genomics on March 21, 2017
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (2009) 67.17
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28
Ovarian cancer development and metastasis. Am J Pathol (2010) 5.92
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
The cellular and molecular origin of tumor-associated macrophages. Science (2014) 3.89
The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med (1996) 3.82
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res (2006) 2.76
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer (2012) 2.74
The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 2.48
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest (2009) 2.42
Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci U S A (2000) 2.36
Nucleosome remodeling at the IL-12 p40 promoter is a TLR-dependent, Rel-independent event. Nat Immunol (2001) 2.34
Robust enumeration of cell subsets from tissue expression profiles. Nat Methods (2015) 2.30
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst (2014) 1.93
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat (2010) 1.64
Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer (2009) 1.62
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer (1995) 1.44
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med (2015) 1.32
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res (2010) 1.31
Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res (2012) 1.28
Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer (2013) 1.27
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res (2008) 1.23
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer (2011) 1.21
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer (2000) 1.17
Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev (2014) 1.14
A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res (2014) 1.12
Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat (2012) 1.11
Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer (2016) 1.08
Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep (2005) 1.07
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology (2015) 1.04
Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol (2004) 1.03
The origin and function of tumor-associated macrophages. Cell Mol Immunol (2014) 1.02
Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer (2010) 0.95
Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol (2012) 0.93
Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer (2016) 0.92
Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer (2006) 0.91
Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecol Oncol (2005) 0.90
In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. Eur J Immunol (2014) 0.90
The transcriptional PPARβ/δ network in human macrophages defines a unique agonist-induced activation state. Nucleic Acids Res (2015) 0.89
Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS One (2010) 0.87
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. Int J Cancer (2009) 0.86
Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. Oncoimmunology (2015) 0.86
The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget (2016) 0.83
A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget (2015) 0.80
Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS One (2015) 0.79
The immune privilege of testis and gravid uterus: same difference? Mol Cell Endocrinol (2013) 0.79
A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol (2016) 0.78
Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers. PLoS One (2014) 0.77
Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer. J Interferon Cytokine Res (2015) 0.77
The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget (2016) 0.83
Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. Oncotarget (2015) 0.79
A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol (2016) 0.78